All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

UCSF Urology Clinicians Present Research Findings at SurgeWest 2025

November 10th 2025

UCSF clinicians present research at SurgeWest 2025, on an RNA biomarker for prostate cancer and opioid prescribing patterns after urologic surgery.

Evolving Post–CDK4/6 Inhibitor Strategies Reflect Need for Precision Approaches in HR+ Breast Cancer

November 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses treatments and targeted therapies in the post–CDK4/6 inhibitor setting of HR+ breast cancer.

Zanzalintinib Plus Atezolizumab Signals New Progress for Previously Treated mCRC

November 10th 2025

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

Five Under 5: Top Oncology Videos for the Week of 11/2

November 9th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC

November 9th 2025

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs

November 8th 2025

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

The OncFive: Top Oncology Articles for the Week of 11/2

November 8th 2025

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer

November 7th 2025

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Giredestrant/Everolimus Opens Doors for Improved SERD Regimens for ER+, Endocrine-Resistant Breast Cancer

November 7th 2025

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma

November 7th 2025

Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.

First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer

November 7th 2025

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

FDA Approves Generic Dasatinib Tablets for CML, ALL

November 7th 2025

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

FDA Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma

November 6th 2025

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

GFH375 Yields Responses, Disease Control in Heavily Pretreated KRAS G12D+ PDAC

November 6th 2025

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Comprehensive Molecular Profiling of Renal Medullary Carcinoma Identifies TROP2 As a Promising Therapeutic Target

November 6th 2025

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC

November 6th 2025

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC

November 6th 2025

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

ChatGPT Fails to Provide Up-to-Date and Specific Information for Specific Queries in Hematologic Malignancies

November 6th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.